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ABSTRACT 
Coronary atherosclerosis with plaque disruption resulting in superimposed thrombosis is 
the main pathological mechanism in the acute coronary syndromes of unstable angina, 
myocardial infarction, and sudden death. In patients with significant obstructive coronary 
disease, high shear flow conditions are created in the stenosed vessel(s) and surface 
bound vWF is essential for platelet adhesion and circulating vWF for aggregation. The 
interaction between GP Ib-IX-V platelet surface complex and vWF is the primary event 
in the formation of an occlusive thrombus under conditions of high shear stress so 
initiating intracellular signalling resulting in activation of the integrin GP Ilb/Illa and 
subsequent platelet aggregation. There is strong evidence that predetermined genetic 
factors, in addition to traditional risk factors for atherosclerosis and arterial thrombosis, 
can influence haemostatic balance and consequently thrombotic risk. A large number of 
genetic polymorphisms have been implicated, mainly by case-control studies, to be 
associated with arterial thrombosis and coronary artery disease. The functional 
significance of some of the genotypes in the setting of coronary artery disease is yet 
unknown. However, my thesis hypothesises that two DNA polymorphisms in the GPlbcc 
gene may be significant factors influencing the risk of myocardial infarction regardless of 
the degree of coronary atheroma. 
Therefore, 256 patients, aged 33-80 were recruited at cardiac catheterisation for any 
diagnostic indication, and divided into two groups: group A, with confirmed previous 
myocardial infarction (98 patients) and group B, with no evidence of myocardial 
infarction (168 patients). All the patients were taking Aspirin 75 mg as their only 
antiplatelet medication. The platelet function was determined based on the closure time 
(CT) measured using PFA-100 with Col/Epi and Col/ADP cartridges in 84 consecutive 
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males from this study group. The plasma level of Von Willebrand factor (vWF) was also 
measured in all patients. 
There was no significant difference in race, age, hypertension, smoking status or family 
history between the infarct and non-infarct groups. Genotype analysis showed an 
association between the GPlb(x -5T/C Kozak homozygous TT genotype and the 
occurrence of myocardial infarction. The TC genotype may have a protective effect 
against MI. No significant association was found between myocardial infarction and the 
GPIb(x VNTR or PL Al /PL A2 , although analysis of the CC VNTR genotype against all 
other GPIb(x VNTR genotypes showed a marginal association with myocardial infarction. 
There was no association between any of the genotypes polymorphism and the degree of 
vessel disease. The platelet reactivity was significantly enhanced in VNTR CC genotype 
using Col/Epi cartridge compared to the BC and CD genotype. In contrast the CD 
genotype had the longest closure time. The TT genotype of the -5T/C Kozak sequence 
polymorphism showed also a marginal increase in platelet reactivity compared to the TC 
genotype. The vWF plasma level was similar in all genotype groups. 
conclude that certain genotypes of GPIb(x (-5T/C Kozak TT and VNTR CC) may 
independently increase the risk of non fatal myocardial infarction regardless of the extent 
of coronary disease. However, none of the polymorphisms studied for the purpose of this 
thesis increased the risk of coronary atheroma. 
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INTRODUCTION 
Vascular injury and thrombus formation are key events in the pathogenesis of acute 
coronary thrombosis. The composition of thrombi found in arterial thrombosis is 
predominantly that of a platelet-rich core attached to an underlying atheromatous 
plaque in an epicardial segment of the corresponding coronary artery branch (Fuster 
V, et al. N Engl J Med 1992, Davies MJ, et al. Eur Heart J 1989). In the arterial 
circulation, platelets adhere to surface bound von Willebrand factor (vWF) via the 
platelet glycoprotein (GP) lb/DUV complex. This receptor is shear dependant and is 
"switched on" in the arterial microvasculature and environments such as those found 
in the coronary artery (Kroll MH, et al. Blood 1996, Roth GJ, et al.. Blood 199 1, 
Berndt MC, et al. Aust NZ J Med 1995, Savage B, et al. Cell 1996). The platelet-collagen 
interaction then leads to activation and expression of functional GPIlb/111a receptors on 
the cell surface (Jang Y, et al. J Am Coll Cardiol 1994). Fibrinogen causes platelet 
aggregation via binding to GPIlb/Illa receptors on adjacent activated platelets (Peerschke 
E17 J Lab Clin Med 1994). Activated platelets also provide a negatively charged 
phospholipid surface necessary for the activation of the coagulation system, with 
resultant generation of thrombin, leading to cleavage of fibrinogen to form fibrin and 
further activation of circulating platelets (Harker LA, et al. Clin Haernatol. 1994). In 
addition the activated platelets release a number of factors leading to activation of factor 
X111, which is essential for cross-linking of fibrin strands, leading to stabilization of the 
fibrin clot (Fitzgerald DJ, et al. Am J Cardiol 199 1) 
Compelling evidence from epidemiological studies suggests a genetic predisposition for 
atherosclerotic disease and arterial thrombosis. (Lane DA, et al, Blood 2000) Not 
surprisingly the platelet surface receptors have been the focus of such genetic researches. 
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Although the results of these published reports are controversial, the jury is still out as to 
whether there is a true association between these genetic polymorphisms and increased 
risk of coronary thrombosis. 
AIM OF THE THESIS 
In this thesis I intend to look at the direct association of some of the GPIb(x and GPIIla 
receptor polymorphisms and coronary thrombosis in subjects in whom the degree of 
coronary disease is known on angiography at the time of blood sampling. This study is 
unique and different from the traditional "case-control" studies. By comparing a 
myocardial infarction (MI) with a non-MI group of patients rather than incorporating a 
traditional "normal control group" we were able to compare two equivalent populations 
who were evenly matched with respect to other known risk factors (Table 1). Within any 
nonnal control group a degree of latent vessel disease would still be expected, therefore 
both the MI and non-Ml cohorts were recruited from patients with known coronary 
angiographic data. Both study groups were well characterised with detailed clinical 
information. This enabled us to dissect out the influence of each of the two 
polymorphisms on the occurrence of MI and degree of vessel disease. 
I looked at the frequency of these genotypes in the study subjects as well the functional 
effect of these genotypes on platelet reactivity. Firstly, the GPIb(x -5T/C Kozak 
polymorphism which may potentially alter the level of expression of GPIb-IX-V, and 
secondly, the GPIb(x variable number tandem repeat (VNTR) which alters the structure of 
this essential platelet adhesion receptor. Thirdly the effect of GP 111a polymorphism on 
platelet aggregation and its association with coronary thrombosis was also evaluated. 
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MEANS OF MEASUREMENTS AND DESIGN OF THE THESIS 
The author recognises that a number of polymorphisms have been described and their 
effects on coronary disease and arterial thrombosis have been reported. For the purpose 
of this study I have only concentrated on some of the most intensively investigated 
genetic polymorphisms of platelet surface receptors GPlbcc and GPIIIa and their function. 
However this study was different from other large published data at the time the research 
was taking place because of the unique design and patient selection. 
The utmost care was taken in the design of the study. The study group was selected from 
patients attending the day case coronary angiography. All our patients underwent 
coronary angiography and fasting blood sampling was done prior to the procedure. All 
patients were taking 75 mg Aspirin as their only antiplatelet therapy and statins in 
addition to other medications. None of the patients received Heparm prior to blood 
sampling. 
Particular attention was given to DNA extraction and polymerase chain reaction (PCR) of 
the DNA to avoid contaminations. The Enzyme Linked hnmuno Sorbent assay (ELISA) 
for von Willebrand factor antigen was done in triplicate and the final result reported as 
the mean of the three results which closely matched. Great care was taken with the blood 
sampling, particularly for the purpose of PFA-100, to avoid over stimulation of platelets 
so the in vitro measurements truly reflect the in vivo. The PFA- IOOTM test was carried out 
in duplicate with both cartridges on 15 healthy volunteers to assure the reproducibility of 
the results hence to ensure the reliability of the method. With each new batch of 
cartridges the reproducibility test was carried with blood sample from a healthy 
volunteer. I myself carried out blood sample collection and all the molecular assays 
including DNA extraction, PCR, ELISA and PFA-100 assays. 
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The experimental work spanned four years and has been published in three peer-reviewed 
papers in 2004-2006 and partly in 1998. The main theme and aim of the research was set 
out at the beginning of my experimental work and the research was carried out at various 
stage of my training. I recognise that since my work was carried out other publications of 
similar work may have emerged but the originality of the thesis at the start of the research 
has been accepted as evidenced by my publications. 
POTENTIAL CLINICAL RELEVANCE AND STATEMENTS OF 
ORIGINALITY OF THE THESIS 
Identifying an association between platelet surface receptor gene polymorphisms and 
coronary thrombosis would help targeted therapy in high risk patients and reduce the risk 
of coronary thrombosis. Evaluation of the polymorphisms of the specific platelet surface 
receptors as an independent risk factor for myocardial infarction may lead to future 
screening in addition to blood glucose, lipids, etc. It will open the doors to possible gene 
therapy for coronary artery disease. 
The entire work of this thesis is original. Most of the work has already been published in 
the journal Heart between 2004 and 2006. The author of this thesis is also the first author 
on all the papers indicating her major contribution to this study (copies of papers 
attached). The techniques of measurements are derived from the literature and adapted 
for the specific purpose 
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CHAPTER 1: PLATELETS AND CORONARY THROMBOSIS 
1.1 LITERATURE REVIEW 
First discovered in 1842 by Donne, (C R Acad Sci, Paris, 1842) platelets and their role in 
different physiological phenomenon and pathological conditions has been the interest of 
many clinicians and scientists over a century. Platelets not only participate in normal 
haemostasis but are also a central element in atherothrombosis, inflammatory and allergic 
reactions, turnour metastasis, etc. In 1882, Bizzozero (Arch Path Anat Physiol. 1882) first 
noted the term "white thrombus" and mechanism of adhesion and aggregation. The 
adhesion of platelets to collagen from an injured vessel with subsequent aggregation was 
first observed in the early 1960s. It was not until twenty years later that a number of 
platelet surface receptors for the initiation of adhesion, activation and aggregation were 
identified. In the last decade it is becoming clear that at high shear, the Glycoprotein (GP) 
Ib-IX-V complex is the pnmary receptor involved in platelet adherence to 
subendothelium, while at a low shear the GP Ilb-Illa serves the function. 
1.1.1 PLATELETS AND ATHEROSCLEROSIS 
Thirty years after Ross et al (N Engl J Med. 1976) proposed the involvement of platelets 
in atherosclerosis, recent evidences have provided insights into the important role of 
activated platelets in the development of atherosclerosis. Detection of activated platelets 
in peripheral blood of patients with unstable atherosclerosis disease was first reported by 
Fitzgerald et al (J Clin Invest. 1986). Circulating activated platelets were also detected in 
the blood of atherosclerotic rabbits (Tsa et al 1994) and patients with stable coronary 
disease (Funnan et al 1J Am Coll Cardiol, 1998). Platelet activation can be seen in 
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different phases of atherosclerosis. In the early phase of atherosclerosis, platelet 
activation as defined by P-selectin surface expression, may be attributed to (a) generation 
of hydroxyl radicals by risk factor; (b) reduction in production of nitric oxide and 
prostacyclin leading to loss of endothelial antithrombotic properties; (c) an increase in 
prothrombotic and pro-inflammatory mediators such as chemokines and tissue factor in 
the circulation. Upon activation, platelets release a wealth of adhesive and pro- 
inflammatory substances. Several groups of these substances such as platelet 
microparticles, platelet derived growth factor, PF-4, EL-1p, CD40 ligand are relevant to 
inflammation and atherosclerosis. Inhibition of thromboxane A2 (TX) production by 
aspirin (Cyrus et al Circulation, 2002) and indomethacin (Pratico et al, Proc Natl Acad 
Sci USA, 2001) or TX receptor by antagonist (Cayatte et al Arterioscler Thromb Vasc 
Biol, 2000) is able to dramatically diminish the formation of the atherosclerotic lesion. 
Also, the effect of aspirin in atherosclerosis may well be explained not only by inhibition 
of TX production but also inhibition of cyclooxygenase-2 in macrophage and smooth 
muscle cells in the vessel wall. Interestingly most risk factors for atherosclerosis 
(diabetes, hypercholesterolemia and smoking) are able to increase the number of 
activated platelets in circulation. (Manduteanu et al J Submicrosc Cytol Pathol, 1992) 
(Broijersen et al, Thromb Haemost, 1998) (Nowak et al, Circulation, 1987). 
1.1.2 PLATELETS AND THROMBOSIS 
Following vessel wall injury as a result of atherosclerotic plaque rupture, platelets 
initially are tethered to the subendothelial extracellular matrix. Under condition of high 
shear rate, this interaction occurs through binding of glycoprotein IbN/IX to immobilized 
vWF. Stable platelet adhesion to the subendothelial extracellular matrix requires 
additional binding of glycoprotein la/Ila, as well as other interactions such as 
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glycoprotein IIb-IIIa-vWF and glycoprotein Ic/Ila-fibronectin. Platelet activation is 
initiated during tethering which results in platelet shape change, release of intracellular 
storage granule contents, expression of the activated form of glycoprotein Ilb/111a and 
other activation markers (e. g. P-selectin) and generation of platelet membrane 
procoagulant activity. Binding of vWF and fibrinogen to activated platelets results in 
platelet aggregation stabilized by the interaction between activated glycoprotein Ilb/111a 
and fibrinogen. 
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Figure 1. Plaque disruption (erosion or overt rupture) is followed by platelet adherence 
that is mediated by specific surface receptors and (GP Ib/IX) and adhesion molecules 
(von Willebrand factor [vWF]). 
subendathelial matFix 
Figure 2. The platelet surface glycoprotein (GP) lb/IX complex binds to von Willebrand 
factor (vWF) affecting adherence to the vessel's subendothelial matrix. 
Figure I and 2 from: Becker RC, Am J Cardiolo 83(9, Symposium 1), pages 3-6 
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1.1.3 PLATELET HYPERREACTIVITY AND CORONARY ARTERY DISEASE 
Enhanced platelet reactivity is well documented in acute coronary syndromes but also in 
patients with stable coronary disease as compared to a healthy population. Platelet 
activation occurs during episodes of chest pain in patients with coronary artery disease. It 
is accepted that such enhanced platelet reactivity has pathological importance and is 
associated with, if not directly responsible for, acute thrombotic events and poorer 
prognosis. Spontaneous platelet aggregation in vitro has been shown as a useful 
biological marker for the prediction of coronary events and mortality in survivors of 
myocardial infarction. It has also been suggested that in vitro analysis of platelet hyper- 
reactivity as measured by PFA-100 is a predictor of the extent of myocardial damage as 
measured by serum creatinine kinase and troponins. Furthermore, trials have 
demonstrated that various antiplatelet drugs including aspirin, clopidogrel and 
glycoprotein Ilb/111a inhibitors provide substantial therapeutic benefit in patients with 
coronary disease and acute coronary thrombosis by reducing platelet activation, 
stabilising plaques, reducing incidence of death or MI and improving prognosis. 
1.1.4 ASSESSMENT OF PLATELET FUNCTION USING PLATELET 
FUNCTION ANALYSER (PFA-100) 
Kratzer and Born (Haemostasis, 1985) first described a system where primary 
haemostasis could be simulated in vitro. An anticoagulated blood sample passes through 
an aperture cut into a membrane coated with collagen and soaked with adenosine 5'- 
diphosphate (ADP). Platelets attach to the area surrounding the aperture and aggregate, 
fonrning a platelet plug that causes stoppage of blood flow through the aperture. The time 
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required for the formation of the platelet plug and the volume of the blood passed through 
the aperture correlated well with the standard clinical tests in patients with a variety of 
platelet dysfunction. The principle conceived by Kratzer et al ((Semin Thromb Hemost 
1995, ). was further developed as a prototyped system, the Thrombostat 4000 and 
subsequently to the PFA- 100. 
The PFA-100 is a high shear-inducing device that simulates primary haemostasis after 
injury to small vessels. The system consists of a microprocessor-controlled instrument 
and a disposable test cartridge. The test cartridge contains a reservoir for citrated whole 
blood and a capillary (200 Vtm internal diameter) surmounted by a cup containing a 
biologically active membrane with a central aperture (150 [tm diameter). The membrane 
is coated with fibrillar type I equine tendon collagen. Additionally, either epinephrine (10 
ýig) or ADP (50 ýtg) is present on the membrane. These agents provide a controlled 
stimulation of platelets as the blood sample passes through the aperture. In response to 
stimulation by collagen and in conjunction with either epinephrine or ADP, as well as 
high shear rates (5000 to 6000 dynes/cm 2 ), Platelets adhere and aggregate on the 
membrane surface at the area surrounding the aperture. Ultimately, a platelet plug forms 
which occludes the aperture and blood flow is stopped. The time required to obtain 
occlusion of the aperture is defined as the closure time (CT). 
The closure time is measured in seconds. The PFA-100 test result is dependent on platelet 
number and function, plasma von Willebrand Factor (vWF) level, hematocrit 
(HCT>28%, measured by our local lab at Hammersmith Hospital) and Aspirin therapy. 
In the haemostasis and thrombosis laboratory and as per manufacturer the normal values 
for closure time with collagen-epinephrine (CEPI) is <164 s and for the collagen-ADP 
(CADP) is < 116 s. The ranges depend on the citrate anticoagulant concentration and the 
choice between glass and plastic collection tubes. Therefore it is reconunended by the 
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manufacturer that each laboratory should determine its own normal range. A non-nal 
CEPI value excludes the presence of a significant platelet function defect. If CEPI is 
prolonged this may indicate "aspirin effect". The CEPI is very sensitive to aspirin in 
many patients and may be greater than 250 s. In contrast CADP is relatively insensitive to 
the aspirin-induced platelet defect. Some of the platelet storage pool and release defects 
can give the "aspirin pattern" on the PFA. The instrument performs a self-test on start up 
that tests the electronics and system vacuum. 
The published coefficient of variation (CV) of the PFA-100 TM in normal subjects ranges 
from 3%-18% with average variability of 8.5%. (Kundu Sk, Semin Thromb Hemost. 1995) 
VaCuum Chuck 
CuWcapillary assembty 
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Capqllafy 
Blood sample 
Housinqýsampfe reservoir 
Fig 1: Schematic view of PFA-100 TM 
Fig 2: PFA- I OOTM machine 
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CHAPTER 2: PLASNa VON WILLEBRAND FACTOR STRUCTURE AND 
FUNCTION 
2.1 LITERATURE REVIEW 
Von Willebrand factor (vWF) is named after Dr Erik von Willebrand (Fin Ldkaresdllsk 
rT- 
handl, 1926) who distinguished von Willebrand disease from other forms of bleeding 
diathesis in families from the Aland islands. It was first purified in 1970 and is a large 
multimeric glycoprotein (>20,000 kDa) present in blood plasma. It consists of over 80 
subunits of 250 kDa each. It is produced constitutively in endothelium (in the Weibel- 
Palade bodies), megakaryocytes (a-granules of platelets) and subendothelial connective 
tissue. 
The basic vWF monomer is a 2050 amino acid protein. Every monomer contains a 
number of functional domains. These include the binding sites for platelet GP lb 
receptor, heparin (Al domain) collagen (A3 and possibly Al domain), Ilb-111a complex 
of platelet surface receptor (C I domain) and factor VIII (D'D3 domain). Their role in 
initiating the thrombosis by platelet-collagen and platelet-platelet interaction is pivotal. 
The vWF multimers are bound to the collagen surface of damaged vascular endothelium 
following an injury. Under conditions of high shear force, the VWF-AI domain 
undergoes conformational. transition from a globular state to an extended chain 
conformation exposing the individual domains and increasing the number of adhesive 
bonds for further platelet surface receptors and collagen causing a more stable and secure 
adhesion of platelets and collagen. This may explain why it is that only the large 
multimers are functional. (Siedlecki CA et al, Blood 1996) 
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There are two ways of detecting vWF in peripheral blood, quantitative and qualitative. 
The quantitative assays detect total vWF but give no accurate infonuation on the 
functional capacity of vWF detected. Qualitative measurements detect only highly 
adhesive vWF and therefore a fraction of the total vWF hence less sensitive assay. The 
vWF: multimer analysis and the vWF : Collagen Binding Activity Assay are all functional 
assays compared to vWF: antigen assay which is the best quantitative assay. The 
vWF: Ristocetin Cofactor assay is both functional and quantitative but has significant 
variability and technical difficulties limit its usefulness. Generally, vWF qualitative 
assays are used in the diagnosis of variant Von Willebrand disease only since the ratio of 
vWF: Antigen to vWF qualitative activity is unity in virtually all patients without Von 
Willebrand disease. 
2.2 VWF AND ARTERIAL THROMBOSIS 
Elevated vWF level is a good index of endothelial cell damage/dysfunction (Blann AD, 
et al Br J Haem 1995)(Pearson JD et al, Br J Haematol 1993). The elevated levels of 
vWF have been reported in numerous cardiovascular conditions and predict poor 
outcome including myocardial infarction, first presentation of ischernic stroke and death 
in prospective studies. (Meade et al, Br J Haernatol 1994)(Kumari M et al, ATVB 
2000)(Bongers T et al, Stroke 2006). 
Factor VIII a pro-coagulant protein is bound to vWF while inactive in circulation and 
degrades rapidly when is released from vWF by the action of thrombin. The level of 
factor VIII coagulant activity correlates well with the vWF antigen level and high FVIII 
levels increase the risk of fatal ischernic heart disease. (Meade et al, Br J Haernatol 1994) 
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CHAPTER 3: GPlb-IX-V and GPIlb-Illa PLATELET SURFACE RECEPTOR 
POLYMORPHISMS 
3.1 LITERATURE REVIEW: GLYCOPROTEIN lb-IX-V COMPLEX 
Each platelet contains 25000 copies of GPIb-IX-V complex. GPfb-IX-V is composed of 
four subunits: GPlb(x, GPlbP, GPIX and GPV, each being the product of a separate 
gene. GPIb(x is disulfide linked to GPIbp forming the heterodimer GPIb, which is non 
covalently associated with GPIX and GPV. (Ruggeri ZM et al, Prog Hemost Thromb 
199 1, Lopez JA. Blood Coagulation and Fibrinolysis 1994, Clemetson KJ et al, 
Seminars in Thrombosis and Haemostasis 1995). The binding site for von Willebrand 
factor (vWF) is located on the (x subunit of GPIb. (Handa M et al, J Biol Chem 1989) 
The major physiological role of the GPIb-IX-V complex is to mediate initial adhesion of 
circulating platelets to surface bound vWF on exposed subendothelial matrix under 
conditions of high shear such as those found in the arterial circulation and stenosed 
vessels. (Savage B et al, Cell 1996, Savage B et al, Curr Opin Hernatol 2001) Other 
potential roles for the GPIb-IX-V complex are to serve as a high affinity cc-thrombin 
binding site and as a receptor that participates in signal transduction to regulate the 
activation state of GPIlb-Illa. (Yamamoto N et al, Throm Res 1985) 
3.1.1 POLYMORPHISMS OF GPlba 
GPIba is the largest glycoprotein of the complex. It contains binding sites for both vWF 
and ot-thrombin . At 
least three polymorphisms may influence the function and surface 
expression of GPIba. These polymorphisms are discussed below. 
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3.1.1.1 VARIABLE NUMBER TANDEM REPEAT (VNTR) 
A variable number of tandem repeat of a 13-amino acid sequence within the mucin-like 
macroglycopeptide region of GPlba and is due to the presence of either one, two, three or 
four copies (alleles D, C, B, A respectively). Each additional repeat of 13 amino-acids is 
0 
predicted to add 32 A to the distance that GPIb(x extends from the platelet surface. 
(Lopez JA, Blood Coagul Fibrinolysis, 1994) 
The four variants of the GPlbcc VNTR range from 168 kDa to 153 kDa, designated A to 
D in order of decreasing molecular mass (D = 1, C=2, B=3 and A=4 repeats)(Ishida F 
et al, Blood, 1995) This results in polypeptide lengths of 610,623,636 or 649 amino 
acids respectively (Lopez JA et al, J Biol Chem 1992). The C allele is the most prevalent 
among all human populations (ranging from 55% among Japanese to 85% among 
Caucasians). The smallest D variant is seen in 33% among Japanese, 8% of Caucasians 
and 4% of black people. The A isoform is found almost exclusively among Eastern Asian 
populations but is rarely present in white European populations. (Ishida F et al, Thromb 
Haemost 1996, and Blood 1995). In a Japanese study, the respective gene frequencies 
were reported to be: 0.35,0.56,0.01,0.073 for D, C, B and A respectively. (Moroi M et 
al, Blood, 1984) It is therefore feasible that the length of GPIb(x could affect the 
efficiency of platelet adhesion owing to differences in the distance between the GPIbu- 
vWF binding site and the vessel wall. 
3.1.1.2 GPlba -5T/C KOZAK SEQUENCE POLYMORPHISM 
Kozak sequences are DNA motifs that surround ATG initiator codons. The sequence 
context of ATG codons is important, in particular the positions -3 to -9. (Kozak M, J Mol 
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Biol 1987) The GPIb(x gene Kozak sequence polymorphism is the result of either aT 
(thymine) or aC (cytosine) at position -5 relative to the ATG start codon. (Kaski S et al, 
Irnmunogenetics 1996) Recently, this Kozak sequence has been reported to affect the 
expression of the GPIb-IX-V complex on the platelet surface. The less common allele C 
is closer to the Kozak consensus sequence, which is said to be more efficient at 
translation, and there is evidence from in vitro studies that it is associated with increased 
expression of the GPIb-IX-V complex on the surface of CHO cells. (Afshar-Kharghan V 
et al, Blood 1999) 
The third polymorphisms of GPlbcc is the Ko (HPA-2) polymorphism. It's association 
with platelet transfusion refractoriness was first described by Saji, et al and Murata et al. 
It is characterized by a C/T transition at nucleotide 1018, resulting in amino acid 
dimorphism (Thr/Met) at residue 145. (Saji H et al, Vox Sang 1989)(Murata M et al, 
Blood 1992) It is in nearly complete linkage disequilibrium with the VNTR. The A and 
B VNTR variants are associated with methionine 145(HPA-2b) and the C and D VNTR 
are linked to the Thr-isoform (HPA-2a allele). Most individuals with the Met allele have 
been reported to carry the B allele but 1-5 % of the B allele carriers are Thr homozygous. 
The allelic frequency in the white population has been reported as 0.89 for HPA-2a and 
0.11 for HPA-2b. (Mazzucato M et al, Transfusion 1996) Thus any association of the 
Met allele with CAD may also be due to an effect of the VNTR polymorphism on platelet 
function. 
3.2 LITERATURE REVIEW: GLYCOPROTEIN Ilb/Illa 
GPlIb-IIIa is a platelet membrane glycoprotein complex important for platelet adhesion 
and aggregation. The complex is an integrin which recognises the arginine-glycine- 
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aspartic acid sequence present on several adhesive proteins such as fibrinogen and von 
Willebrand factor. GPIlb consists of two disulfide-linked subunits, GPUb (MW=125,000) 
and GPII (MW=23,000) while GPIlIa has only one polypeptide chain (MW= 108,000). 
The Fibrinogen binding site is located on GPIIIa. The role of GP Ilb-111a in arterial 
thrombosis and the inhibition of this receptor is a major therapeutic advance in the 
management of coronary thrombosis. The use of anti glycoprotein Ilb-Illa receptor 
antibodies (known as Abciximab) has been shown to improve the outcome in patients 
with acute coronary syndrome and post-angioplasty. 
3.2.1 POLYMORPHISMS OF GPIlb-Illa 
GPffb-Illa is highly polymorphic and carries PL A '/PL A2 . (Kunicki TJ et al, Blood 1992) 
A2 There is geographical variation in the prevalence of PL . (Kim HO et al, Transfusion 
1995)(Odawara M et al, Lancet 1996) The PL A'/]PL A2 polymorphism, also known as 
HPA-la/HPA-lb, is due to a substitution of Leu-33 to proline in theP3-subunit of GP Ilb- 
111a. This results in an extracellularly positioned conformational change of theP3-subunit. 
Therefore it has been considered biologically plausible to suggest a potential impact of 
Leu33Pro on platelet aggregation. 
CHAPTER 4: FUNCTIONAL SIGNIFICANCE OF PLATELET SURFACE 
RECEPTOR POLYMORPHISMS 
4.1 LITERATURE REVIEW: 
4.1.1 GPIbu VNTR AND INCREASED RISK OF CORONARY ARTERY 
DISEASE AND ARTERIAL THROMBOSIS 
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This polymorphism may have important implications for the function of GP lba, as each 
added repeat would position the ligand-binding region further away from the platelet 
membrane surface, making it more accessible to ligand binding and more susceptible to 
shear forces. Several studies have assessed the relationship between the GP Iba-VNTR 
and risk of thrombotic disease but the findings have been inconsistent. In a Japanese 
study of 91 patients with non-fatal MI or angina and 105 healthy volunteers, Murata et al. 
(Circulation 1997) reported an increase risk of coronary heart disease associated with the 
presence of the B or A allele. However this association was not seen in another study. (Ito 
T et al, Int J Hematol, 1999). 
A case control study from Spain using risk factor-matched subjects without any vascular 
disease demonstrated a 2-fold increase in risk of both coronary heart disease and 
ischernic cerebrovascular disease associated with the presence of BC-VNTR genotype 
but no association was seen with deep venous thrombosis. (Gonzalez-Conejero R, Blood 
1998). No association was found between VNTR genotype and risk of myocardial 
infarction in France (Mercier B et al, Thromb Haemost, 2000) or stroke in the UK (Carter 
AM et al, Arterioscler Thromb Vasc Biol, 1998). 
4.1.2 GPIba -5T/C KOZAK AND RISK OF CORONARY ARTERY DISEASE 
AND ARTERIAL THROMBOSIS 
An effect of the glycoprotein Ib(x Kozak sequence -5T to C substitution on translation 
efficiency is supported by the studies of Afshar-Khargan et al (Blood, 1999) who 
demonstrated increased surface levels of the GPIb-IX-V receptor on platelets carrying the 
-5C allele as well as 
CHO cells transfected with the -5C variant. In contrast, flow 
cytometric analysis of a larger number of individuals did not confirm the relationship 
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between -5 T/C genotype and platelet surface glycoprotein lb(x density among T/T and 
T/C individuals, although subjects carrying the C/C genotype were not examined (Corral 
J et al, Thrombosis Haemost, 2000). Cadroy Y et al (Blood 2001), using a parallel-plate 
perfusion chamber, reported a positive association between -5T/C polymorphism in the 
Kozak sequence and acute arterial thrombosis that is dependent on the local blood flow 
condition. The increase in platelet deposition was only seen in vitro at a physiological 
shear rate of 650/s and no difference was observed at the shear rate of 2600/s. Favaloro 
EJ et al 2002, using the PFA-100, found a shorter collagen-epinephrine-induced closure 
time in homozygotes with the (-5)T/T compared to (-5)C/T genotype. 
This T/C polymorphism has also been identified to be associated with ischemic stroke. 
(Baker R et al, Blood 2001). A Japanese study reported an increased risk of ischemic 
stroke among patients carrying at least one copy of the -5C allele and the association was 
independent of the effect of other polymorphism (Sonoda A, Thrombosis Haemost, 
2001). In contrast,, in a population based study of North American young women with 
myocardial infarction, no association was seen between -5C allele and increased risk of 
MI or stroke, in fact, the C allele was less common among women with MI (Frank MB et 
al, Blood, 2001) 
4.1.3 PL A' AND PL A2 AND RISK OF ARTERIAL THROMBOSIS 
A2 
Platelets from PL - positive individuals show increased aggregability compared with 
platelets from PL 
A2 
- negative individuals using a platelet aggregorneter (Michelson AD et 
al, Thromb Haemost 2000)(Feng D et al, Arterioscler Thromb Vasc Biol 1999). The 
association of this polymorphism and ischernic coronary syndrome was also shown in 
other studies. (Weiss EJ et al, N Engl J Med 1996)(Pastinen T et al, Hum Mol Genet 
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1998). However, some investigators found no association between PL A2 genotypes and 
myocardial infarction. (Hermann SM et al, Thromb Haemost 1997) (Samani NJ et al, 
Cardiovasc Res 1997). Ridker PM and co-authors (Lancet 1997) found that the relative 
risk for any vascular event among men homozygous or heterozygous for PL A2 compared 
with men homozygous for PL Al was 0.96 (95% CI 0.8-1.2). They also found no 
association between the PL A2 allele and myocardial infarction, stroke or venous 
thrombosis in subgroup analysis by traditional cardiac risk factor and aspirin intake. The 
meta-analysis of mainly case-control studies with conflicting results encompassing more 
than 17,000 individuals, aggregated results showed an odd ratio for ischen-ýc 
cardiovascular disease in PL 
Al /PL A2 heterozygotes combined with PL 
A2 /PL A2 
homozygotes versus PL Al /PL A1 noncarriers of 1.1 (95% confidence interval 1.03 to 
1.18). The Copenhagen City Heart Study with 22 years follow up of the patients showed 
PL A2 /PL A2 homozygosity increased risk of ischemic cardiovascular and myocardial 
infarction in younger men. 
CHAPTER 5: METHODS 
5.1 PATIENTS AND CONTROLS 
The study group consisted of 256 patients aged 33-80 years who were admitted for 
cardiac catheterisation for angina or reasons other than chest pain at Hammersmith 
hospital over a period of six months. This study was approved by the Research Ethics 
Committee. All patients gave informed consent. The clinical data was collected from a 
patient questionnaire (figure a) and from the patients' medical notes. Patients were 
divided into two matched groups according to their clinical history. Group A: 88 patients 
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with a definite previously diagnosed myocardial infarction (MI) and Group B: 168 
patients with no previous myocardial infarction, with either normal or diseased coronary 
arteries (non-MI group) (Table I and 2). On presentation to the catheterization laboratory, 
the history of MI was established based on documented evidence in patients' hospital 
records or by ECG (Q wave) or ventriculogram (area of akinesia). 
For the functional study PFA-100 was only carried out on 84 patients (Table 2). These 
patients were consecutive males selected from the 256 patients who had been genotyped 
for the VNTR and -5T/C Kozak sequence polymorphisms of the GPlba receptor. 
All the patients were fasting and taking 75mg aspirin as their only antiplatelet therapy. 
All patients with cholesterol above 5 mmol/litre were taking statins or other antilipid 
therapy. None of the patients received Heparin prior to blood sampling. All the patients 
were reminded to take their aspirin on a daily basis prior to blood sampling except on the 
day of the testing. They were also asked to abstain from smoking and alcohol for at least 
12 hours. Patients who had suffered myocardial infarction within the previous 6 months 
were excluded from the study. The atherosclerosis risk factors were defined as: 
hypercholesterolernia (>5.2mmol per litre or on cholesterol lowering drugs), hypertension 
(blood pressure >140/90 mm Hg or on anti-hypertensive medication), smoking (at 
presentation), diabetes mellitus and a positive family history (Ist degree relatives) of 
ischemic heart disease (1141)). The coronary arteriograms were interpreted by a single, 
independent observer. Each of the three main coronary vessels was considered to be 
diseased when the lumen was reduced to less than 50% of the normal diameter. We also 
recorded patients with minor atheromatous coronaries (irregularities on angiogram) 
without any significant stenosis and patients with normal coronaries in one sub group 
because of small sample group of patients with normal coronaries. 
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Separately, we also recruited 25 healthy volunteers (doctors and nurses, aged 25-50) 
without any significant cardiac risk factor or bleeding abnormality who were able to take 
aspirin 75mg for three days. The Ethics conunittee approved this late addition to the 
original study. The main purpose of recruiting a group of healthy volunteers was to 
determine our own laboratory normal range for vWF assays and PFA-100 prior to taking 
aspirin and after 3 days of taking aspirin. 
5.2 BLOOD SAMPLING 
Patients had routine blood tests (FBC, renal and liver function test) prior to their coronary 
angiography. Patients with anaernia and impaired renal or liver function were excluded 
from the study. 
In addition to their routine blood sampling, 20 ml of blood was collected between 8am - 
1 lam using a 21 gauge siliconised "butterfly" cannula (Abbott Co. Ltd. UK) without 
using a cuff. The blood was then transferred into two 4 ml of tubes containing 3.13% tri 
sodium citrate at a concentration of I part citrate to 9 parts blood. The first 4 ml was used 
for vWF: Ag assay; the second 4 ml. citrated blood was used to measure platelet function 
with the PFA- IOOTM . The remainder of the 
blood was stored into two 6 n-d tubes that 
contained Ethylenediamine Tetracetic acid (EDTA) at -70'C for subsequent DNA 
extraction. 
5.3 VON WILLEBRAND FACTOR ANTIGEN ASSAYS 
Since the aim of the study was to assess the functional effect of a rise in plasma vWF in 
patients with coronary disease it seemed reasonable to use a quantitative assay to quantify 
the rise in plasma vWF and not compromise on sensitivity. We selected the vWF: Ag 
assay as the best quantitative and highly sensitive assay. The enzyme 
linked 
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immunosorbent assay (ELISA) method was used to measure plasma vWF: Ag. The blood 
was collected into 3.2% citrate for vWF: Ag assay. The citrated blood was immediately 
centrifuged at 3000 rpm for 10 minutes, separated into Retic tubes and stored at -800C 
for analysis as part of a batch. The frozen plasma was thawed only once at 370C, 30 
minutes before use. Anti-human vWF. Ag (DAKO A082) was diluted 1: 500 in 0.05M 
carbonated buffer (40ýtl antibody in 20ml buffer). Each well of the microtitre plate was 
coated with 100 ml of diluted antibody and wrapped in parafilm and incubated for one 
hour at room temperature in a moist chamber. The test plasma ware then diluted in 1: 10, 
1: 20,1: 40 with 0.01M Phosphate buffered saline (PBS), PH 7.2 added to the wells and 
incubated for one hour to allow the vWF. Ag to bind to the primary antibody. After 
removal of excess antigen by washing the plate a second antibody, anti-human vWF. Ag- 
peroxide conjugate, called "tag" antibody (DAKO P226) is added and incubated again for 
another hour, and this binds to the vWF. Ag already stuck to the plate. On addition of a 
specific substrate (colour reagent Ortho-phenylenediamine mixed with citric acid, 
Na2HP04.12H20 and hydrogen peroxide) a colour change occurs. After the reaction has 
been stopped by LOM sulphuric acid, the optical density (OD) of each well can be 
measured using an electronic plate reader (DYNATECH MR 700) and the OD is 
directly 
proportional to the amount of vWF. Ag present in test plasma. The machine calculates the 
standard curve and gives an R2 value. Results under 0.25U/ml or over 
LOOU/ml should 
be disregarded. To calculate the results multiply the 1: 20 result by 2 and the 1: 40 result 
by 4. The final result is obtained by taking a mean of the three calculated results, which 
should be closely comparable. The normal range established 
locally, is 0.5-2.0 U/rrd. 
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5.4 PFA-100 PLATELET FUNCTION ANALYSER 
Platelet reactivity was assessed using PFA- I OOTM system (Dade Behring, supplied by 
Sysmex UK Ltd. ) as previously described. 
Briefly, the citrated blood was allowed to stand for 30-60minutes only, 800 pl of whole 
blood was added to standardized, disposable cartridge and incubated at 38.50C. The blood 
was then aspirated at high shear rate (5000/s) through a ring coated with 2 ýtg equine type 
I collagen and 50 ýig ADP. Platelets adhere to the ring and become activated forming an 
aggregate which occludes the opening. The time to occlusion (closure time, CT) was 
taken as a measure of platelet reactivity, shorter time indication greater activity. All the 
tests were performed by the same operator. A self-test and maintenance was carried out 
daily and with each new lot of cartridges a normal control sample was to assure proper 
instrument performance. The reproducibility of test variables was determined by 
comparing the results on both channels using the blood samples from the 25 healthy 
volunteers on two different occasions before and after taking aspirin 75 mg. 
The coefficient of variation for closure time ranged from 5.2% and 11.2% before taking 
aspirin and 8.3 % and 13.1 % after taking aspirin. The PFA- 100 sensitively detected the 
effect of aspirin. The average of coefficient of variation was 9.2% (less than 10% is 
acceptable). The closure time for Col/Epi in 95% of these selected individuals after 
taking aspirin was 100-200sec and for Col/ADP 80-120sec. Therefore, we accepted these 
values as the normal range for the purpose of our study. 
5.5 DNA EXTRACTION 
Genomic DNA was extracted from whole blood stored in EDTA tubes using BACC2 
Nucleon kit (Nucleon Biosciences, Lanarkshire, Scotland). 
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The process of DNA extraction is described according to different phase of the 
procedure. 
1. Cell preparation: Under aseptic technique 10ml of whole blood was diluted with 
Reagent A then rotary mixed for 4 minutes and centrifuged at 1300g (2400rpm) for 5 
minutes. Without disturbing the pellet the supernatant was discarded. 
2. Cell lysis: To the pellet Reagent B was added and incubated for lOn-dnutes at 
37T. 
3. Deproteinisation: 500ýd of sodium perchlorate solution was added to the mix. 
4. DNA extraction: 2ml of Choloroform. was added and mixed by inverting at least 7 
times. Then 300ýd of Nucleon resin was added, centrifuged at 1300g (2400rpm) for 3 
minute. 
5. DNA precipitation: without disturbing the resin layer, the DNA containing upper 
phase was transferred to a new 1.5ml tube. 2 volumes of cold ethanol were added to the 
tubes and inverted several times until the DNA strands appeared. These were then 
spooled using out of the solution using a sterile innoculation loop. The DNA was re- 
dissolved in sterile DNase free water by mixing on a rotary mixer for 2 hours. 
5.6 DNA GENOTYPING 
VNTR GENOTYPE POLYMORPHISMS 
The DNA sequence spanning the GPIb(x VNTR polymorphism was amplified by 
polymerase chain reaction (PCR) of genomic DNA using Red Hot DNA polymerase 
(Advanced Biotechnologies, Surrey, UK) and the following primers: 5' 
ATCCACTACTGAACCAACCC3'nt 4199-4218 and 5' 
GAGTGATACGGGTTTTGTGG 3' nt 4451-4432 (GenBank Accession no. AC22403). 
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An initial DNA denaturation at 96'C for 5 minutes was followed by 32 cycles of 45 sec 
denaturation at 96C, I minute annealing at 55'C, and 2 minutes extension at 720C. A 10 
minute final extension at 72'C completed the reaction. 
10ýd of the PCR products and the restriction digests were analysed on 2.5% agarose gels 
(Seakem ME, FMC products, Maine, USA). The DNA fragments amplified were as 
follows: D allele 253bp, C allele 292bp, B allele 33 lbp and the A allele 370bp. 
1- C/C 
2. C/C 
3. C/A 
4. C/C 
5. C/B 
6. C/D 
7. Marker Ladder 
GPlbcc -5T/C KOZAK SEQUENCE POLYMORPHISMS 
The DNA sequence spanning the -5T/C Kozak polymorphism was amplified using the 
primers Kozak 15' GGGAGTAGGGAGGACAGGAG 3' and Kozak2 
5'AGTGTAAGGCATCAGGGTTG 3'. Amplification conditions were as above but with 
an annealing temperature of 59'C and using a hot start technique. The 348bp PCR 
products were subject to overnight digestion at 37'C with the restriction enzyme Avall 
which recognises the T allele resulting in two fragments of 129 + 219bp. Any apparently 
homozygous CC patients were checked with Haelll. In the presence of the C allele, 
Haelll generates two fragments of 130 +218bp. 
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allele 
Undigested Fragments 
C allele 
348 1 348 
Dige3tion with Avall 
I 
-219 j11 
130 1 
17n 1 
129 129 89 
348 
Di gesti on with Haelll 
130 218 
3456 
Marker Ladder 
2. T/T 
3. Uncut PCR 
4 to 8. T/T 
9. T/C 
10 and ll. T/T 
12. C/C 
13 and 14 T/T 
10 11 12 13 14 
PL A' AND PL A2 POLYMORPHISMS 
The DNA sequence spanning the PL Al /PL A2 polymorphism was amplified using the 
primers GP3Aplal 5'TTCTGATTGCTGGACTTCTCTT3' and GP3aPL A2 
5'TCTCTCCCCATGGCAAAGAGT 3'. Amplification conditions were as above but 
with denaturation at 94'C and annealing temperature of 53'C without using a hot start 
technique. The 266bp PCR product was then digested with the restriction endonuclease t) I 
Msp I and run on 3% agarose gel and visualized using ethidium brormide. The 
A 
Ie homozygous PL 1 after d to:, stion with Msp I results in two fratc), ments 221+45. Any 
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apparently homozygous PL A2 patients were checked with Nci I which recognizes the 
PL A2 allele resulting in two fragments 216 and 50bp. 
PLA1 allele 
51 
MSPI 
G 1ý coprotein IIIa gene 
1 
266 
1 
Undigested fragments 
1 
221 
1 
Digested with Msp I 
1 
266 
1 
Digested with No I 
PLA2 allele 
Nol 
mspi msp I 
1 
266 
d 
177 
H45 
216 
1 
1. PLA1/PLA1 uncut 
2. PLA1/PLA1 cut using Msp 1 
3. PLA1/PLA1 cut using Nci 1 
4. marker ladder 
5. PLA1/PLA2 uncut 
6. PLA1/PLA2 cut using 
Msp 1 
7. PLA1/PLA2 cut using Nci 1 
8. PLA2/PLA2 uncut 
9. PLA2/PLA2 cut using 
Msp 
10. PLA2/PLA2 cut using Nci I 
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CHAPTER 6: STATISTICAL ANALYSIS 
Genotype distribution in cases and controls were examined for significant deviation 
(p<. 05) from Hardy Weinberg equilibrium. Association analysis was performed using the 
statistical package SPSS version 12. To compare the groups for family history, diabetes 
mellitus, hypertension, cholesterol and smoking effect in different genotype groups we 
used Chi-square or Fishers exact test. The effect of age was analyzed as a single 
continuous variable using linear regression analysis of variance (ANOVA). The influence 
of genotype was assessed using Pearson Chi square. P values less than 0.05 were 
considered to be statistically significant. 
CHAPTER 7: RESULTS 
7.1 CLINICAL CHARACTERISTICS OF STUDY GROUP 
The study group consisted mainly of Caucasian (n=180) and males (n=180). Fifty 
patients were treated diabetic and 75 patients were hypertensive. Hypercholesterolemia 
was seen in 116 patients. Fifty-six patients were current smokers and 193 patients were 
ex-smoker or none smokers. One hundred and thirty four patients had family history of 
ischemic heart disease (first degree relatives). For the purpose of this thesis the total of 
patients were divided into two groups: patients with myocardial infarction (MI) and those 
without MI (no MI). The clinical characteristic of the total study group 
is shown in table 
1. 
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Table 1. 
Characteristics and prevalence of risk factors for Ischemic Heart Disease in the two 
subgroups with and without Myocardial Infarction 
mi No MI p value t 
(n=88) (n= 168) Odds Ratio (95% CI) 
* Age 
Range (years) 35 -78 33-80 p= 0.117 
Mean (SD) 59.06 (9.90) 56.96 (10.58) 
Sex (%) 
Male 79(89.8) 101(60.1) p< 0.00001 
Female 9(10.2) 67(39.9) OR 5.82 (2.61-13.38) 
(')Race 
Indian Asian 24(27.3) 51(30.5) p= 0.586 
Caucasian 64(72.7) 116(69.5) OR 1.17 (0.64-2.17) 
Risk Factors 
(12) Family history (%yes) 51(60.7) 83(51.9) p= 0.187 
(% no) 33(39.3) 77(48.1) OR 1.43 (0.81-2.54) 
(3) Diabetes (%yes) 22(25.3) 28(16.9) P= 0.110 
(% no) 65(74.7) 138(83.1) OR 1.67 (0.85-3.28) 
(5) Hypertension (%yes) 30(34.9) 45(27.3) p= 0.211 
(% no) 56(65.1) 120(72.7) OR 1.43 (0.78-2.60) 
Cholesterol (%yes) 46(52.9) 70(41.7) p= 0.088 
(%no) 41(47.1) 98(58.3) OR 1.57 (0.90-2.74) 
(7) Smoker (%yes) 20(23.8) 36(21.8) p= 0.72 
(% no) 64(76.2) 129(78.2) OR 1.12 (0.57-2.18) 
(16) Ex-smoker (% yes) 49(60.5) 83(52.2) p= 0.22 
(% no) 32(39.5) 
------------------ 
76(47.8) 
------------------------------ 
OR 1.40 (0.79-2.74) 
--------------------------- ------------------------------------ 
(n) Indicates the number of missing values 
p values are indicated together with the Odds 
Ratio and (95% confidence intervals) 
I also looked at clinical characteristics of the 
84 male patients selected for functional 
study. The comparison was 
done by dividing the patients into two groups: patients with 
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documented myocardial infarction (n=28) and those without MI (n=56). The 
characteristics and prevalence of risk factors for Ischemic Heart Disease in the two 
subgroups are shown in table 2. 
Table 2: 
mi No MI p value 
Age years, mean(SD) 63(6.1) 61(9.1) 0.223 
Smoker, n(%) 9(32.1) 12(21.4) 0.21 
Diabetes, n(%) 7(25) 13(23.2) 0.53 
Hypertension, n(%) 23(82.1) 41(73.2) 0.267 
Hypercholesterolemia, n(%) 8(28.6) 15(26.8) 0.529 
vWf Ag level, U/ml, mean (SD) 1.15(0.79) 1.0(0.44) 0.21 
7.2 RESULTS IN RELATION TO THE EXTENT OF CORONARY 
ATHEROMA 
I also looked at the correlation between the severity of coronary disease and increased 
risk of myocardial infarction (table 3). The difference in the degree of vessel disease 
between the MI and non-MI groups was highly significant, p<0.001. Multivessel disease 
was more frequent in patients with previous MI than those without MI. The non-MI 
patients were mostly those with normal coronaries. 
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Table 3: 
The distribution and severity of vessel disease detected by coronary angiography in the 
MI and non-Ml patient groups 
Vessel disease mi 
0* 2 (2.3%) 79 (47.0%) 
xt 4 (4.6%) 14 (8.4%) 
it 10(11.5%) 17 (10.1%) 
2t 24(27.3%) 23 (13.7%) 
3t 46(52.3%) 35 (20.8%) 
*0 indicates normal coronaries 
X indicates irregularities on angiogram 
1,2 and 3 indicate the number of diseased vessels. 
§There were 2 subjects in the MI group whose degree of vessel disease was unavailable. 
The sub analysis for the 84 patients is different because of small sample group. The 
extent of coronary disease were divided into those with normal coronaries or minor 
No MI 
iffegularies but without significant stenosis and those with one or more vessel disease. 
Vessel disease MI(%) No MI (%) 
No vessel disease(%) 
One vessel 
p value 0.664 
12(42.8) 
16(57.2) 
27(48.2) 
29(51.8) 
In this small group of patients the only significant atherosclerosis risk factor to influence 
the severity of coronary disease was hypercholesterolernia. 
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Table 4: 
Cardiac risk factor (p value) Normal coronaries 
Number (%) 
More than one VD 
Number (%) 
Smoking (p=0.08) 21(38%) 35(62%) 
Hypercholesterolernia (p=0.0001) 15(13%) 101(87%) 
Diabetes (p=0.45) 25(50%) 25(50%) 
Hypertension (p=O. 12) 31(42%) 44(58%) 
- Age (p=0.27) 61+9.2 63+7.4 
7.3 VWF ANTIGEN LEVEL 
Plasma von Willebrand factor antigen level was similar in MI and non-MI groups. The 
analysis of all genotypes also revealed similar plasma level in all genotype subgroups. 
(Figure 1) However, there was a difference in the plasma level of vWF in patients with 
coronary disease than those without (0.88+0.02 vs 1.06+0.59, p=0.003). However, the 
difference in the plasma vWF did not have any effect on the closure times measured by 
Col/Epi and Col/ADP cartridges in patients with normal coronaries and those with at 
least one or more diseased vessels. (Table 5) 
In the 25 healthy controls group the vWF plasma level was 1.07+0.59. 
7.4 PLATELET FUNCTION 
The results of Platelet reactivity as measured by PFA- 
100 using collagen-epinephrine and 
collagen-ADP cartridges are shown here. 
The extent of coronary vessel disease appears 
to have no effect on platelet function (table 5). 
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Table 5: The platelet reactivity as measured by PFA-100 using Col/Epi and Col/ADP 
cartridges in relation to the degree of vessel disease 
Col/Epi closure time (sec)* Col/ADP closure time (sec 
Normal coronaries 252+82 93+28 
One or more vessel disease 00 193+88 98+25 
P=U. / 
Results are Mean + SD 
No difference was seen in plasma vWF level and platelet reactivity in patients with 
previous myocardial infarction and those without MI. (table 6) 
Table 6: The vWF plasma level and platelet reactivity as measured by PFA-100 using 
Col/Epi and Col/ADP cartridges in MI and non-Ml patients 
vWF level (U/ml)* Col/Epi closure time (sec) t Col/ADP closure time (sec)** 
MI 1.15+0.79 190+99 103+36 
No MI 1.0+0.44 200+82 96+18 
9 p=0.2, t p=0.12, **p=0.07 
0 Results are Mean + SD 
Diabetes mellitus appears to be the only cardiac risk factor to marginally influence the 
platelet function observed by both Col/Epi and Col/ADP channels. (Table 7) 
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Table 7: Effect of Cardiovascular Risk Factors on Platelet Function 
Cardiac risk factor Col/Epi Col/ADP P value 
Smoking Yes 177.4+88.8 115.5+31.7 0.88 
No 173.6+82.1 103.9+25.8 
Hypercholesterolernia Yes 169.8+83.9 99.5+19.7 0.6 
No 17.3+82.1 109.5+29.8 
Diabetes Yes 159.6+67.9 106+26.6 0.05 
No 179.2+86 108+28.2 
Hypertension Yes 181.5+85 106.4+25.2 0.2 
No 152.2+69.3 108+35.2 
9 Results are Mean + SD 
Table 8: Platelet function in patients with or without history of myocardial infarction 
Usin2 Col/Epi cartridge 
closure time <100; closure time =100-199 sec closure time >200 sec 
mi 10(35.7) 10(35.7) 
Non-Ml 8(14.3) 29(51.8) 
8(28.6) 
19(33.9) 
p value 0.07 
Values are number 
Usim Col/ADP cartridgEs 
closure time <80 sec closure time =80-119 sec closure time >120 sec 
3(10.7) 18(64.3) 7(25) 
Non-Ml 6(10.7) 34(60.7) 16(28.6) 
p value 0.939 
Values are number (%) 
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7.5 GPlba POLYMORPHISMS 
7.5.1 FREQUENCY OF GPlba VNTR AND -5T/C KOZAK SEQUENCE 
POLYMORPHISMS 
The frequency of the VNTR and -5T/C Kozak sequence polymorphisms in total 
population are shown in table 9 and 10. The frequency of these genotypes in our study 
group is similar to previously reported data. The frequency of theses genotypes were also 
analysed in sub-groups of patients with or without a history of myocardial infarction. 
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7.5.2 VNTR POLYMORPHISMS AND RISK OF MYOCARDIAL INFARCTION 
Genotype distribution of the GPlb(x VNTR polymorphisms between the MI and no-Ml 
patient groups is shown in table 10. No significant association was found between the 
VNTR genotypes and MI, p=0.60. 
Considering the CC genotype v all other VNTR genotypes, there was a marginal 
association, p=0.059, OR 1.8,95%Cl 0.94 - 3.48. 
--------------------------------------------------------------------------------------------------------- 
VNTR AC BC BD cc CD DD 
MI n=88 (%) 0(0.0) 6(6.8) 3(3.4) 69(78.4) 8(9.1) 2(2.3) 
No MI n=168 (%) 1(0.6) 23(13.6) 2(1.2) 113(67.3) 27(16.1) 2(1.2) 
--------------------------------------------------------------------------------------------------------- 
7.5.3 GPIba -5T/C KOZAK POLYMORPHISMS AND RISK OF 
MYOCARDIAL INFARCTION 
Genotype distribution of the GPlba -5T/C Kozak sequence polymorphisms between the 
MI and no-MI patient groups are shown in this table. 
------------------------------------------------------- 
-5T/C Kozak TT 
------------------------------ 
TC cc 
MI n=88 M 75 (85.2) 
No MI n=168 (%) 113(67.3) 
11(12.5) 2(2.3) 
55(32.7) 0(0.0) 
A significant association was found between the -5T/C Kozak TT genotype and MI, 
p<0.00 1, OR 2.10,95 % Cl 1.11 - 4.02 
The TT v TC+CC Kozak genotype also shows a significant association with MI, 
p=0.002, OR 2.81,95% Cl 1.37 - 5.82. 
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7.5.4 EFFECT OF GPIba POLYMORPHISMS ON PLATELET REACTIVITY 
Comparison of GPlb(x-VNTR and -5T/C Kozak sequence genotypes on closure time 
measured by PFA- IOOTm are shown. Platelet reactivity was significantly enhanced in the 
VNTR CC compared with BC and CD genotype (mean (SD), closure time: 117.66 
(46.41) sec, closure time: 167.35 (73.3) sec, closure time: 247.96 (67.54) sec 
respectively, p=0.001) using Col/Epi cartridges. (Figure 1) A greater number of CC 
VNTR subjects had a closure time less than 100sec. (43%CC, 17%BC, O%CD, p=0.0001). 
In contrast, the CD genotype had the longest closure time measured by Col/Epi (69%, 
CT>200, p=0.0001). The TT genotype of the -5T/C Kozak sequence polymorphism 
showed a marginal increase in platelet reactivity compared to the TC genotype (26% v 
12.5 % for closure time <IK 23 %v 46% for closure time >200, p=0.05). No difference 
was seen in closure time measured by Col/ADP channel. 
Table 11: 
Using Col/ Evi cartridge 
Genotype closure time <100 sec closure time =100-199 sec closure time >200 sec 
CC VNTR 13(43.3) 15(50) 2(6.7) 
BC VNTR 5(17.9) 16(57.1) 7(25) 
CD VNTR 0 8(30) 18(69.2) 
value 0.0001 
TT Kozak 14(26.9) 26(50) 12(23.1) 
TC Kozak 4(12.5) 13(40) 15(46) 
p value 0.05 
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Using Col/ADP cartridge 
Genotype closure time <80 sec closure time = 80-119 sec closure time >120 sec 
CC VNTR 3(10) 20(66.7) 7(23.3) 
BC VNTR 3(10.7) 17(60.7) 8(28.6) 
CD VNTR 3(11.5) 15(57.7) 8(30.8) 
p value 0.971 
TT Kozak 6(21.5) 31(59.6) 15(28.8) 
TC Kozak 3(9.4) 21(65.6) 8(25) 
p value 0.857 
Values are number (%) 
7.6 GPIlb-Illa POLYMORPHISM 
7.6.1 FREQUENCY OF THE PL 
Al /PL A2 POLYMORPHISMS 
PL A genotype distribution in our study group was similar to previously reported data and 
did not differ from Hardy-Weinberg equilibrium. 
Genotype distribution and allele frequency of the GPIlb-Illa polymorphism in the study 
group 
----------------------- 
Genotype 
--------------- 
Al/Al 
---------- 
Al/A2 
-------------------- 
A2/A2 
------------------ 
------------------------------------- 
Allele Al 
------------------------------------- 
---------- 
A2 
---------- ----------------------- 
% distribution 
--------------- 
71.6 
---------- 
26.3 
-- 
2.1 85 15 
n=256 184 67 5 n=512 
435 77 
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7.6.2 CORRELATION BETWEEN THE PL A' AND PL A2 GENOTYPES AND 
MYOCARDIAL INFARCTION 
The genotype frequency and risk of myocardial infarction 
--------------------------------------------------------------------------------------------------------- 
PL Al/Al PL AUA2 PL A2/A2 
MI n=88 68(77.3) 18(20.5) 2(2.2) 
No MI n=168 (%) 116(69.3) 49(29) 3(1.7) 
P value=0.63 
7.6.3 CORRELATION BETWEEN THE PL A' AND PL A2 GENOTYPES AND 
SEVERITY OF CORONARY DISEASE 
The PL A1 and PL A2 genotypes had no effect on the degree of coronary atheroma. 
Although not statistically significant, there is a suggestion that homozygosity for PL A2 is 
associated with more severe coronary disease. 
Vessel disease Al/Al Al/A2 
------- 
0* 
----------------- 
(n=8 1) 
---------------------------- 
60(74%) 
---------------------- 
21(26%) 
xt (n=18) 9(50%) 9(50%) 
1ý (n=27) 21(77.7%) 5(18.5) 
2ý (n=47) 34(72.3%) 11(23.5%) 
3ý (n=8 1) 60(74%) 19(23.6%) 
------------------------- 
A2/A2 
0 
0 
1(3.8%) 
2(4.2%) 
2(2.4%) 
------------------------------ 
7.6.4 VWF LEVEL IN SUBGROUPS OF PL 
A' AND PL A2 GENOTYPES 
The von Willebrand factor level was similar in the three groups. Although there was a 
trend toward slightly raised plasma vWF in PL 
A2 allele. 
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7.6.5 PL Al AND Pl, A2 GENOTYPES AND PLATELET REACTIVITY 
PL Al and PL A2 polymorphisms had no effect on the platelet function. The closure time 
using collagen-ADP cartridges was 95-4+24.3 sec for PL A' heterozygotes, 90.7+24.2 sec 
for PL A' homozygotes and 105+14.4 sec for PL A2 homozygotes. Also no effect was 
detected using Col/Epi cartridges. The closure time using Col/Epi are as follows: 
Al/Al Al/A2 A2/A2 200.4+82.7 secs for PL , 190.3+99.7 secs for PL , 193.2+88.9 secs for PL 
(Figure 4). 
7.7 EFFECT OF COMBINED GENOTYPES ON PLATELET FUNCTION 
7.7.1 COMBINED GPlba VNTR AND -5T/C KOZAK SEQUENCE 
POLYMORPHISMS ON PLATELET FUNCTION 
The combined effect of VNTR polymorphisms and -5T/C Kozak sequence 
polymorphism on closure time in response to Col/Epi or Col/ADP is shown in table 12. 
Patients with combined CC VNTR/TT Kozak genotypes demonstrated the shortest 
closure time and patients with the CD VNTR/TC Kozak polymorphisms had the longest 
closure time (mean (SD), closure time: 104.05 (26.2) v 276.9 (50.1), p=0.002). 
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Table 12: 
Genotypes Col/Epi closure time Col/ADP closure time 
BC + TC* 201.45(82.61) 103.72(19.56) 
N=I I 
BC + TT* 145.29(59.04) 108.35(29.64) 
N=17 
CC + TC* 144.9(65.25) 105.2(36.32) 
N=10 
CC + TT* 104.05(26.2) 106.95(26.79) 
N=20 
CD + TC* 276.9(50.1) 113.72(34.29) 
N=I I 
CD + TT* 226.73(72.19) 103.26(23.48) 
N=15 
P value 0.002 0.839 
*-5T/C Kozak sequence polymorphism 
N number 
Values are mean(SD) 
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GENERAL CONCLUSIONS 
Coronary atherosclerosis with plaque disruption resulting in superimposed thrombosis is 
the main pathological mechanism in the acute coronary syndromes of unstable angina, 
myocardial infarction and sudden death with the amount and extent of associated 
thrombus formation affecting the final clinical outcome (Fuster V, et al. N Engl J Med 
1992). The composition of thrombi found in arterial thrombosis is predominantly that of a 
platelet-rich core attached to an underlying atheromatous plaque in an epicardial segment 
of the corresponding coronary artery branch (Davies MJ, et al. Eur Heart J 1989). Blood 
passing through arteries that have been narrowed by atheroma will be subjected to higher 
local shear forces resulting in the possibility of increased risk of thrombotic occlusion via 
the shear dependant vWF and GPIb-1X-V interaction. It therefore appears that platelet 
adhesion to vascular sub-endothelium and subsequent platelet aggregation, are critical 
elements in the mechanism of coronary thrombosis (Fuster V, et al. Circulation 1990). 
In the arterial circulation, platelets adhere to surface bound von Willebrand factor 
(vWF) via the platelet glycoprotein (GP) Ib-IX-V complex. This receptor is shear 
dependant and is "switched on" in the arterial microvasculature and environments 
such as those found in the coronary artery (Kroll MH, et al Blood 1996, Roth Gj, Blood 
1991, Berndt MC, et al, NZ J Med 1995, Savage B, et al, Cell 1996). 
There is an increasing body of evidence that predetermined genetic factors can influence 
haernostatic balance and consequently thrombotic risk (Lane DA, et al, Blood 2000). We 
hypothesized that two DNA polymorphisms in the GPlb(x gene may be significant factors 
influencing the risk of myocardial infarction (MI). Firstly, the GPIb(x -5T/C Kozak 
polymorphism which may potentially alter the level of expression of GPIb-IX-V, and 
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secondly, the GPIb(x variable number tandem repeat (VNTR) which alters the structure of 
this essential platelet adhesion receptor. 
We designed this study to explore the potential of the -5T/C Kozak and VNTR 
polymorphisms of GPIb(x to act as independent risk factors for MI. By comparing a MI 
with a non-Ml group of patients rather than incorporating a traditional "normal control 
group" we were able to compare two equivalent populations who were evenly matched 
with respect to other known risk factors (Table 1,2). Within any normal control group a 
degree of latent vessel disease would still be expected, therefore both the MI and non-Ml 
cohorts were recruited from patients with known coronary angiographic data. Both study 
groups were well characterised with detailed clinical information. This enabled us to 
dissect out the influence of each of the two polymorphisms on the occurrence of MI and 
degree of vessel disease. 
The pathogenesis of thrombosis hinges on an imbalance in the haemostatic system 
and polymorphisms of candidate coagulation genes have therefore been the targets of 
recent study. For example the PL A2 allele of GPlIla has been associated with MI at a 
young age and also been linked with sudden death due to MI in a series of middle 
aged men (Ardissino D, et al, Blood 1999, Mikkelsson J, et al, Arterioscler Thromb 
Vasc Biol 1999). 
Arterial thrombosis occurs predominantly in the older population and is affected by many 
environmental factors that may also act synergistically with pre-existing genetic 
influences. The GPlb-IX-V receptor functions within a high shear envirom-nent and 
altered binding to vWF due to changes in structure or levels of surface expression may 
therefore be associated with the development of coronary thrombosis and subsequent MI. 
The Kozak - 5T/C and VNTR polymorphisms of the GPlbcc gene may therefore 
hypothetically modulate the efficiency of platelet adhesion in the arterial 
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microvasculature. If this were the case, the genotype distribution may be expected to vary 
significantly between a group of patients with MI and a matched group without MI. 
The results of our study show a significant difference in the genotype frequencies 
between the two study groups. In particular, the TT Kozak genotype was more frequent 
among those patients with MI and Kozak TC genotypes were more frequent in those 
patients without MI. Based on the in vitro work it might be expected that the -5CIC 
genotype would confer the greatest risk (Afshar-Kharghan V, et al, Blood 1999). 
Paradoxically, the results of our study suggest that the presence of the -5T/T genotype in 
2 the Kozak sequence is significantly associated with the occurrence of MI, , 
7=9.56, p= 
0.002, OR 2.81,95%CI 1.37 to 5.82. Furthennore, it could be argued that the presence of 
the Kozak C allele may confer a degree of protection against a coronary event when 
present in the heterozygous state (TC 12.5% in MI, 32.7% in non-MI). This may give the 
impression that the TT genotype is associated with increased risk. Clearly the Kozak - 
5T/C polymorphism has a potentially significant association with coronary thrombosis 
completed by MI and this will need a larger prospective study for clarification. 
An elegant in vitro study in CHO cells investigated the effect of the T and C Kozak 
alleles on surface expression of GPIb-IX-V and suggested that the Kozak C allele results 
in increased expression of the complex that may correlate with increased platelet 
adhesion (Afshar-Kharghan V, et al, Blood 1999). However, studies in a static tissue 
culture system do not replicate the physiological environment that exists in the high shear 
forces of the arterial vasculature on which the adhesive function of this complex depends. 
It must also be considered that other regulatory sequences and transactivating factors may 
modulate in vivo gene expression (McBratney S, et al, Molecular and Cellular Biology 
1996). It is therefore still credible that aC allele may confer protection, or alternatively a 
T allele act as a potential risk factor in the physiological situation. 
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Published data so far is inconsistent in its findings. In a series of CHD and CVA 
(cerebrovascular accident) patients, GPIb-IX-V expression was apparently not associated 
with the -5T/C Kozak dimorphism and showed no association with arterial thrombosis 
(Corral J, et al, Thrombosis and Haemostasis 2000). 
A short report has found no association between the -5T/C Kozak sequence 
polymorphism and MI. (Croft SA, et al, Blood 2000) Their study populations however 
had significant differences in hypertension, cholesterol and particularly in smoking and 
diabetes between the normal and patient groups. Although the numbers tested were 
higher, this is not a truly matched control group and for neither patient nor control 
population were details of coronary vessel disease provided The data published from a 
series of non-fatal stroke and non-fatal MI in young women, suggested that the presence 
of aC allele apparently reduced the risk of MI in agreement with our results, but had no 
effect on CVA (Frank MB, et al, Blood 2001). Our study was based on MI survivors and 
this may mask the true effect of genotype on risk. Interestingly, in our study, the only 2 
patients who were CC were in the MI group although this number is too small for 
statistical analysis. It could be argued, that if patients with sudden death due to acute 
coronary syndromes could be included, then a different picture of genotype v risk would 
emerge. The number of subjects in this study, although relatively small, still had adequate 
statistical power to provide valuable data. A much larger prospective study will address 
this issue. 
A recent study of 1461 white participants genotyped for 85 genetic variants found no 
association between any of the genotypes and acute coronary syndrome. (Morgan TM et 
JAMA. 2007 ). The negative results in their study may be explained by varied effects 
of risk variants in different genetic backgrounds. Their results does not bear on the 
validity of positive associations reported in different populations and clinical 
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subgroups(eg, analyses sub stratified by age, sex or a clinical variable, such as 
hypertension, hyperlipidemia or smoking status). 
Although our study population consisted of patients undergoing an invasive diagnostic 
procedure, some with suspected coronary artery disease, the overall distribution of alleles 
and genotypes observed was consistent with previous reports, based on general 
population screening. This study therefore provides some evidence that genetically 
determined differences in the structure of GPlbcc may partly determine the risk of 
developing coronary thrombosis with consequent MI. It is interesting that no relationship 
was found between the severity of atheroma (stenosis) and the GPlb(x VNTR or -5T/C 
Kozak genotypes, therefore the differences in risk associated with these polymorphisms 
appear to be more closely linked to thrombosis than to atheroma. 
As the arterial lumen narrows in atheromatous coronary artery disease the turbulent flow 
increases the shear forces. The presence of atheroma appears to be a necessary, but not 
sufficient factor, for the occurrence of coronary thrombosis. This study was designed to 
elucidate the frequency of genotypes in coronary artery disease completed by thrombosis. 
It was therefore quite appropriate that the whole study population, including the controls, 
be recruited from a population of patients likely to have atheromatous coronary disease 
rather than a population of healthy volunteers. No significant difference was found 
between the two study groups in the prevalence of established risk factors for coronary 
disease (Table 1,2) and therefore no further stratification of the sample was necessary. 
The different GPlb(x VNTR polymorphic variants determine the distance between the 
vWF binding domain and the platelet surface. Some of these could create a minor spatial 
advantage for platelet adhesion to exposed vascular sub-endothelium. It has been implied 
that a longer GPIb(x polypeptide may lower the threshold of shear force required for 
55 
platelet adhesion to immobilised vWF (Lopez JA, et al, The J Biol Chem 1992). A 
geometrically balanced arrangement of multiple complexes based on a hypothetical 
conformation of four copies of GPlb-IX-V and two copies of GPV has been proposed 
(Lopez JA, et al, Advances in Vascular Biology, Volume Six, Platelets, Thrombosis and 
the Vessel Wall, 2000). The adhesion efficiency of the complex may therefore have 
subtle differences depending on whether it is assembled from GPlb(x VNTR alleles of 
either equal or unequal length. In this study the CC VNTR genotype showed a marginal 
2 association with MI when compared against all other VNTR genotypes, , = 
3.57, p= 
0.059, OR 1.80,95%CI 0.94 to 3.48 (Table 9). However, in a previous study of 
Mediterranean Caucasian patients the C/B VNTR genotype was reported as showing an 
association with CVA and CHD but not DVT in a study of patients in the age range 34- 
85(Gonzales-Conejero R, et al, Blood 1998). All patients had individually matched 
controls with no documented history of heart disease, although no information was 
available regarding the degree of vessel disease. In a cohort of Japanese patients, the A 
allele showed an association with CHD (Murata M, et al, Circulation 1997). As reports to 
date are inconsistent, a definitive answer will require a much larger prospective study to 
elucidate any potential association with CHD and MI. 
The homozygous state also appears to be an important factor as the VNTR CC genotype 
was more frequent (78.4% v 67.3%) and the CD genotype less frequent (9.1% v 16.1%) 
among the patients with MI compared to those without MI respectively. Why expression 
of a shorter GPIba receptor component may be associated with MI is open to speculation 
and further in vitro and in vivo studies are required. 
As a result of our first study, we postulated that the difference in risk associated with 
these polymorphisms appear to be more closely linked to thrombosis than to atheroma. 
To further evaluate this hypothesis we designed this study to look at the effect of these 
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polymorphisms on platelet function of the same group of patients with or without 
angiographic evidence of coronary atherosclerosis using a method that mimics 
pathophysiological conditions in vivo involving platelet binding to vWF binding under 
condition of high shear stress. We therefore used the platelet function analyser, PFA- 
IOOTM that measures the time taken for platelet adhesion/aggregation to occur in response 
to collagen under conditions of high shear following activation by epinephrine or ADP 
(Mammen EF, et al, Semin Thromb Haemost 1998) 
Having shown that the GPlb(x genotypes CC of the VNTR and Kozak -5TT increase risk 
of non fatal myocardial infarction, we then hypothesized that these genotypes increase 
the risk of platelet plug formation under the condition of high shear stress generated by 
stenosed vessels hence increasing the risk of myocardial infarction. 
There have been variable reports of closure time values as measured by the PFA- IOOTM in 
the literature. The influence of various factors, including blood collection, food and 
diurnal variability on platelet function as assessed by the PFA-10OTm, has been reported 
(Mani H, et al, Platelets 2004, Paglieroni TG, et al, Vox Sang. 2004, Dalby MC, et al, 
Platelets. 2000). 
The effect of various cardiac risk factor and degree of vessel disease on the closure time 
as measured by the PFA- IOOTM is reported in table 5-7. The effect of different genotypes 
on the platelet function is shown in table 11. These results are in some agreement with 
the recent study that showed the shortest closure time in individuals carrying the Kozak - 
5TT or VNTR CD genotypes. However, the individuals 'n this study were young healthy 
male and female not taking aspirin (Jilma-Stohlawetz P, et al, Br J Haernatol. 2003). Our 
study group consists of older males who have been taking aspirin for a considerable 
period of time. We also showed that patients with combined VNTR CD and Kozak -5TC 
genotype have the longest closure time in response to aspirin thus lower risk. It is 
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possible that the VNTR B and D alleles and the C allele of the -5T/C Kozak 
polymorphism may have a protective effect. 
Enhanced platelet reactivity is well documented in acute coronary syndromes, even in 
patients with stable coronary disease compared to a healthy population (Gawaz M, et al. 
Thromb Res. 1996, Furman MI, et al. J Am Coll Cardiol. 1998). 
It is accepted that such enhanced platelet reactivity has pathological importance and is 
associated with, if not directly responsible for, acute thrombotic events and poorer 
prognosis (Frossard M, et al. Circulation. 2004, Funnan MI, et al. J Am Coll Cardiol. 
2001). Furthermore, treatments that reduce platelet activation are known to stabilise 
plaques, reduce the incidence of death or MI and improve prognosis (Fuster VV, et al. 
Cuff Cardiol Rep. 1999, Peterson JG, et al. Am J Med. 2000, Helft G, et al. 
Arterioscler Thromb Vasc Biol. 2000). In our study we found a marginal increase in 
platelet reactivity in patients with a history of acute myocardial infarction (table 6). We 
demonstrated that more MI patients had the shortest closure time compared to non-MI 
patients, although, this did not reach statistical significance. This can be explained by the 
relatively small sample size particularly in the case of MI patients (28 v 56). 
We found no correlation between the severity of coronary artery disease (CAD) and 
platelet function (table 5). This is consistent with the finding that, in patients with stable 
angina, the degree of luminal narrowing does not predict the likelihood of future 
myocardial infarction (Ambrose JA, et al. Heart 1998). However patients with raised 
cholesterol seem to have more severe CAD. This is consistent with previous studies 
showing that hypercholesterolemia is one of the most significant risk factors for the 
severity of CAD (Wang XL, et al. Circulation 1994). 
In contrast to ADP and thrombin, epinephrine is a weak activator of human platelets. It 
interacts with a-adrenergic receptors on platelets and synergistically enhances the effects 
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of other aggregating agents (Lanza F, et al. Am J Physiol. 1988). It has also been 
suggested that the occurrence of stress related myocardial ischaemia and infarction may 
be related to haernodynamic and cardiovascular effects of sympathetic mediators and 
increasing plasma levels of epinephrine in the circulation (Dakak N, et al. Am J Cardiol. 
1995). Generally, the closure time will be prolonged with the Col/Epi cartridge, but 
non-nal or near normal with the Col/ADP after the intake of aspirin (Mammen EF, et al. 
Sernin Thromb Hemost 1995). In our study the effect of genotypes on the platelet 
function was only observed with Col/Epi not Col/ADP regardless of aspirin intake. 
This thesis would indicate that GPIba genotypes CC of the VNTR and Kozak -5TT 
polymorphisms are more closely associated with thrombosis than atheroma. We postulate 
that it is likely that genotypic variation in the GPIb(x receptor may have functional 
significance perhaps resulting in increased binding to vWF. It has been suggested that in 
patients with longer GPIb(x receptors (i. e. those with 3 or 4 tandem repeats), where the 
vWF-binding domain will be further away from the platelet surface membrane, surface 
bound vWF is more easily accessible to the binding site on that receptor (Lopez JA, et al. 
J Biol Chem 1992). However, in our study the VNTR CC genotype (2 tandem repeat) 
seems to be associated with increased platelet reactivity. We could hypothesize that a 
physically shorter receptor that brings the platelet into closer proximity with the sub- 
endothelial surface can result in more efficient binding and subsequently marginally 
increase the risk of coronary event. Additionally, a GPIb-IX-V receptor that has a 
heterozygous GPIb(x genotype as in the CD VNTR, could be less favourable for efficient 
binding to surface bound vWF on damaged sub-endothelium under shear due to the 
unequal lengths of the GPlb(x glycoprotein and this is supported by the increased closure 
times seen with the CD VNTR genotype in this study. 
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The effect of a substitution of proline for leucine on glycoprotein 111a function is unclear. 
The presence of a proline in the peptide chain determines a different tertiary structure of 
the glycoprotein and this has been confirmed by previous reports of a different 
immunophenotype of the two polymorphic variants (Weiss EJ et al. Tissue Antigens 
1995). 
The PL A2 polymorphism of GPIlb-Illa has been shown to be a strong independent risk 
factor for coronary thrombosis and the association with coronary thrombosis was found 
to be stronger in patients under the age of 60 years at the time of their acute myocardial 
infarction. (Weise et al N Engl J Med. 1996). This previously described association of 
myocardial infarction with the PL A2 polymorphism of the glycoprotein 111a, receptor gene 
is not evident in our study population. The prevalence of this polymorphism was similar 
in our group of patients with a previous myocardial infarction to that of our control group 
and is almost identical to that in the control Population of the study reported by Weiss et 
al. This polymorphism was found in 23% of the patients with previous myocardial 
infarction and in 31% of the patients with no previous myocardial infarction (p = 0.5 3). 
There was also no significant association with the extent of coronary disease. There is no 
evidence, therefore, from this study of an association between the PL Al /PL A2 
polymorphisms and the occurrence of myocardial infarction. 
The results of these two studies would not necessarily be contradictory if the presence of 
the PL A2 polymorphism was associated with an increased mortality rate after hospital 
discharge, as our patients were sampled an average of 60 months following the 
occurrence of myocardial infarction. The patients reported by Weiss et al. were sampled 
in the acute phase of myocardial infarction, during hospital admission. The results of our 
study are consistent with those reported by Marian et al (Curr Opin Cardiol. 1998). and 
Carter et al(Arterioscler Thromb Vasc Biol. 1998). who were also unable to document an 
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association between PLA2 and myocardial infarction. However, in these two reports the 
interval between myocardial infarction and the subsequent blood sampling for DNA 
extraction is not specified. The control group in our study is particularly appropriate to 
the study of coronary thrombosis and myocardial infarction as they had 53% had 
angiographic evidence of coronary artery disease. They are therefore very similar to our 
patient group, differing mainly by the absence of coronary thrombosis and myocardial 
infarction. The results of our study therefore do not exclude an association between 
coronary atherosclerosis and the PL A2 polymorphism. 
The controls in the study by Weiss et al. were acutely ill patients with no evidence of 
ischemic heart disease, those of Marian et al. were healthy volunteers and the report by 
Carter et al. did not specify the nature of the control population. Our study population 
consisted of patients of both European (n = 180) and Asian (n = 75) origin. Only white 
patients were enrolled in the studies of Weiss et al. and Carter et al. The fact that 29.4% 
of our study population were of Indian Asian origin, the distribution of European and 
Asian patients between our two study groups was similar. Furthermore, the prevalence of 
the PL A2 polymorphism in our control group was similar to that of the control groups of 
European origin in the above mentioned studies and was also similar to that found by 
other authors in northern and central Europe (von dem Borne et al Transfusion 1990). 
The main purpose of this study was to establish a correlation between the VNTR and - 
5T/C Kozak gene polymorphisms of the GPlbcc platelet surface receptor and its function 
in males with documented coronary artery disease. We recognize the limitations of this 
pilot study. Our study population is small and did not include the less frequent VNTR A 
allele and homozygous CC -5T/C Kozak. A larger study may be required to fully assess 
the true implications of these genotypes in clinical practice and recognition of high-risk 
patients with CAD. 
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In summary, the preliminary findings of this study provide some evidence to suggest that 
genetically determined variations in the structure and expression of the platelet GPlb(x 
receptor could potentially influence the risk of developing coronary thrombosis and 
myocardial infarction. We have demonstrated that men with known coronary artery 
disease and CC VNTR or TT -5T/C Kozak genotypes for the platelet GPIba receptor 
have greatly enhanced platelet reactivity to collagen in the presence of epinephrine under 
high shear compared to those with the CD, BC VNTR and TC Kozak genotype. This 
suggests an association between platelet hyper-reactivity and GP Ib(x receptor length 
polymorphism and the expression of the surface receptor. Taken in conjunction with our 
earlier demonstration of a link with risk of myocardial infarction we now propose a 
mechanistic connection between the genetically determined functional variants of this 
platelet surface receptor and its precise role as a risk factor for arterial thrombosis. 
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Figure 1: Effect of VNTR polymorphisms on the platelet function measured by PFA-100 
using Collagen/ADP and Coll agen/Epinephrine channels t-D 
63 
Col/Epi Col/ADP 
=0.002 
400 
300 
200 
100 
0 
U 
OTT OTC 
p =0.67 
Figure 2: Effect of -5T/CKozak sequence polymorphism on the platelet function 
measured by PFA-100 using Collagen/ADP and Collagen/Epinephrine channels 
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Figure 3: Effect of Combined VNTR and -5T/CKozak sequence polymorphisms on 
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